<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953275</url>
  </required_header>
  <id_info>
    <org_study_id>20160543</org_study_id>
    <nct_id>NCT02953275</nct_id>
  </id_info>
  <brief_title>Synergistic Effect of Vedolizumab and Pentoxifylline</brief_title>
  <official_title>Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the synergistic effect and clinical benefits of
      vedolizumab and pentoxifylline in the management of patients with inflammatory bowel disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients in clinical remission</measure>
    <time_frame>week 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of new major and minor infections</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of episodes of nephrotoxicity</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of episodes of hepatotoxicity</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of episodes of myelosuppression</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>vedolizumab plus pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vedolizumab plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vedolizumab</intervention_name>
    <description>standard of care</description>
    <arm_group_label>vedolizumab plus pentoxifylline</arm_group_label>
    <arm_group_label>vedolizumab plus placebo</arm_group_label>
    <other_name>Entyvio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>added to vedolizumab</description>
    <arm_group_label>vedolizumab plus pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>added to vedolizumab</description>
    <arm_group_label>vedolizumab plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active Crohn's disease (CD) defined by blood lab values, stool markers,
             abnormal MR enterography imaging, or colonoscopic findings

          -  Patients who are good candidates to start standard dosing of vedolizumab

          -  Patients who have not used an off-label or investigational drug for CD in the 8 weeks
             prior to screening

          -  Patients who have met the washout period of 8 weeks for infliximab, 4 weeks for
             certolizumab pegol, and 2 weeks for adalimumab if there is a history of anti-TNF
             exposure and 8 weeks if there is a history of exposure to natalizumab

          -  Oral aminosalicylates are allowed during the study, provided that the dose has been
             stable for at least 2 weeks prior to screening

          -  Oral corticosteroids are allowed provided that the dose is prednisone ≤40 mg/day or
             equivalent and/or budesonide ≤9mg/day and has been stable for at least 2 weeks prior
             to screening

          -  Patients are able to discontinue thiopurines (azathioprine and 6-mercaptopurine) or
             methotrexate upon initiation of vedolizumab

          -  Rectal therapies, narcotics, anti-diarrheals, probiotics, and antibiotics will be
             permitted at investigator discretion

        Exclusion Criteria:

          -  Contraindications or history of allergy to PTX

          -  Known interaction of PTX with patient's current medications

          -  Use of an off-label or investigational drug for CD in the 8 weeks prior to first VDZ
             infusion

          -  Pregnancy

          -  GFR &lt;30 at any time in the 6 months prior to first infusion of VDZ

          -  Documented cirrhosis

          -  Age &lt;18 or &gt;80 years old

          -  Contraindication to colonoscopy at 24 week study time-point
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar R Deshpande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Morillo</last_name>
    <phone>305-243-6405</phone>
    <email>dmorillo@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Crohn's and Colitis Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Morillo</last_name>
      <phone>305-243-6405</phone>
      <email>dmorillo@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Amar R Deshpande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Amar Deshpande</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

